New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges
about
Antifungal Therapy: New Advances in the Understanding and Treatment of MycosisEvaluation of anti-Candida activity of Vitis vinifera L. seed extracts obtained from wine and table cultivarsCandida albicans Niche Specialization: Features That Distinguish Biofilm Cells from Commensal Cells.Fungal vaccines and immunotherapeutics.News from the fungal front: wall proteome dynamics and host-pathogen interplayInduction of caspase-11 by aspartyl proteinases of Candida albicans and implication in promoting inflammatory response.Vulvovaginal Candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF Registry No. 015/072, S2k Level, December 2013)Mycobacterium tuberculosis Zinc Metalloprotease-1 Elicits Tuberculosis-Specific Humoral Immune Response Independent of Mycobacterial Load in Pulmonary and Extra-Pulmonary Tuberculosis Patients.Genetically Engineered Virus Nanofibers as an Efficient Vaccine for Preventing Fungal Infection.Candida antigens and immune responses: implications for a vaccine.Newer patents in antimycotic therapy.Codetection of Trichomonas vaginalis and Candida albicans by PCR in urine samples in a low-risk population attended in a clinic first level in central Veracruz, Mexico.Vaccines and immunotherapy against fungi: the new frontier.Immunobiological Activity of Synthetically Prepared Immunodominant Galactomannosides Structurally Mimicking Aspergillus Galactomannan.NLRP3 inflammasome is a key player in human vulvovaginal disease caused by Candida albicans.The evaluation of β-(1 → 3)-nonaglucoside as an anti-Candida albicans immune response inducer.Candida albicans: Clinical Relevance, Pathogenesis, and Host Immunity
P2860
Q28818603-543835E1-45C1-4F2A-86BA-563C11100D5CQ33598045-9926FB85-AE77-4549-AD3C-A0767EEC62B6Q33603993-5689890B-7EA4-4C03-A145-706E3E37A0C1Q34400249-B868F46F-6BE1-4D19-859A-941A8D639B60Q34539765-8AE56F9F-E305-4A1E-B872-852F7742DBCBQ35439961-24BC3C26-8257-48C0-A3D0-5F8E79862685Q36743194-2283F721-A46E-46C5-A136-75D32ABBA75EQ36747054-833AB6D0-08E9-4AF3-BF89-E050B151EC09Q36788780-85DE8D2F-6986-40FF-AE9A-51B56E431381Q38222636-73AFF636-D43E-4152-ADDD-16F0FCB7A82EQ38743672-77427C5E-006D-4775-AEEA-5D6B31CF8CDAQ41827849-DB3DA8AF-C711-4C69-9FEB-35EE41E604C0Q42002277-47DDE4C3-B957-4615-A1ED-C6928408F704Q42683287-85825705-12DB-4EDA-A959-F71CC74BB811Q47138065-0DB3340B-5A4F-4DD8-A9E8-65A6C0F9A518Q51699904-66A9C8D0-9BC4-49FE-ABA3-FBAE2BDF0436Q59282466-6C32AAA5-174A-47A5-AB02-221C121F38C5
P2860
New approaches in the development of a vaccine for mucosal candidiasis: progress and challenges
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
New approaches in the developm ...... iasis: progress and challenges
@ast
New approaches in the developm ...... iasis: progress and challenges
@en
type
label
New approaches in the developm ...... iasis: progress and challenges
@ast
New approaches in the developm ...... iasis: progress and challenges
@en
prefLabel
New approaches in the developm ...... iasis: progress and challenges
@ast
New approaches in the developm ...... iasis: progress and challenges
@en
P2093
P2860
P356
P1476
New approaches in the developm ...... iasis: progress and challenges
@en
P2093
Donatella Pietrella
Elena Gabrielli
Eva Pericolini
P2860
P356
10.3389/FMICB.2012.00294
P577
2012-08-13T00:00:00Z